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https://doi.org/10.1053/j.gastro.2020.04.058BACKGROUND & AIMS: Homozygosity for the Pi*Z variant of
the gene that encodes the alpha-1 antitrypsin peptide (AAT),
called the Pi*ZZ genotype, causes a liver and lung disease
called alpha-1 antitrypsin deficiency. Heterozygosity (the
Pi*MZ genotype) is a risk factor for cirrhosis in individuals
with liver disease. Up to 4% of Europeans have the Pi*MZ
genotype; we compared features of adults with and without
Pi*MZ genotype among persons without preexisting liver
disease. METHODS: We analyzed data from the European
Alpha-1 Liver Cohort, from 419 adults with the Pi*MZ geno-
type, 309 adults with the Pi*ZZ genotype, and 284 individuals
without the variant (noncarriers). All underwent a compre-
hensive evaluation; liver stiffness measurements (LSMs) were
made by transient elastography. Liver biopsies were analyzed
to define histologic and biochemical features associated with
the Pi*Z variant. Levels of serum transaminases were
retrieved from 444,642 participants, available in the United
Kingdom biobank. RESULTS: In the UK biobank database,
levels of serum transaminases were increased in subjects with
the Pi*MZ genotype compared with noncarriers. In the Alpha-1
Liver Cohort, adults with Pi*MZ had lower levels of gamma-
glutamyl transferase in serum and lower LSMs than adults
with the Pi*ZZ variant, but these were higher than in non-
carriers. Ten percent of subjects with the Pi*MZ genotype vs
4% of noncarriers had LSMs of 7.1 kPa or more (adjusted odds
ratio, 4.8; 95% confidence interval, 2.0–11.8). Obesity and
diabetes were the most important factors associated with LSMs
7.1 kPa in subjects with the Pi*MZ genotype. AAT inclusions
were detected in liver biopsies of 63% of subjects with the
Pi*MZ genotype, vs 97% of subjects with the Pi*ZZ genotype,
and increased with liver fibrosis stages. Subjects with the Pi*MZ
genotype did not have increased hepatic levels of AAT, whereas
levels of insoluble AAT varied among individuals. CONCLU-
SIONS: Adults with the Pi*MZ genotype have lower levels of
serum transaminases, fewer AAT inclusions in liver, and lower
liver stiffness than adults with the Pi*ZZ genotype, but higher
than adults without the Pi*Z variant. These findings should helpdetermine risk of subjects with the Pi*MZ genotype and aid in
counseling.Keywords: FibroScan; SERPINA1; GGT; ALT.
lpha-1 antitrypsin (AAT) is produced predominantlyAin hepatocytes, secreted into the bloodstream, and
then transported to the organs where it fulfills its physio-
logical functions as an anti-protease.1 However, approxi-
mately 10% of Europeans carry a genetic variant in
SERPINA1 (the AAT gene), as more than 100 different mu-
tations are known.2 Mutations in SERPINA1 typically inter-
fere with its production/secretion.1,3 Among the SERPINA1
variants, a glutamate-to-lysine substitution at position 342,
termed “Pi*Z,” is the most clinically relevant one.1,3
Compared with “Pi*Z,” a glutamate-to-valine substitution
at position 264, termed “Pi*S,” is clinically less severe.2
Pi*Z in its homozygous form, known as “Pi*ZZ” genotype
or severe AAT deficiency (AATD), confers a strong suscep-
tibility to early-onset lung emphysema as well as liver
disease, that together constitute the major causes of Pi*ZZ-
related mortality.1,3,4 Notably, Pi*ZZ subjects can be easily
WHAT YOU NEED TO KNOW
BACKGROUND
Homozygosity for the Pi*Z variant in the gene that
encodes alpha-1 antitrypsin (AAT) increases risk for liver
fibrosis. We investigated the effects of heterozygosity
(the Pi*MZ genotype) in different European cohorts.
FINDINGS
Adults with the Pi*MZ genotype have lower levels of
serum transaminases, fewer AAT inclusions in liver, and
lower liver stiffness than adults with the Pi*ZZ genotype,
but higher than adults without the Pi*Z variant.
IMPACT
This information should improve counseling and
management of Pi*MZ individuals.
LIMITATIONS
Many adults with the Pi*MZ genotype do not develop
symptoms or have a known family history of AAT
deficiency and, as a consequence, remain undetected
— our findings might not apply to this population.
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LIVERidentified in the clinical routine due to their substantially
reduced serum AAT levels.1,3
Two large cross-sectional studies demonstrated signifi-
cant liver fibrosis (defined as fibrosis stage 2) in 20% to
35% of Pi*ZZ individuals4,5 and in line with that, Pi*ZZ in-
dividuals carry an approximately 20 times increased risk to
require liver transplantation.6 The pathological hallmark of
Pi*ZZ-related liver disease is the retention of misfolded,
insoluble AAT in hepatocytes that leads to formation of
roundish AAT inclusions.2,7 These aggregates are rather
indistinct in the routine hematoxylin and eosin labeling but
appear brilliant red in periodic acid–Schiff–diastase (PAS-D)
staining.2,5 In addition, they can be visualized with immu-
nohistochemistry against the Pi*Z variant.
Although the Pi*ZZ genotype is rare (prevalence
w1:3000 in Europeans), heterozygous Pi*Z carriage, termed
“Pi*MZ” genotype, occurs in approximately 1:30 to 1:40
Europeans.1 In contrast to Pi*ZZ, that is sufficient to cause
end-stage liver disease on its own, the Pi*MZ genotype is
primarily considered a disease-modifying factor in in-
dividuals with other liver diseases. Its relevance has been
particularly well documented in individuals with cystic
fibrosis as well as alcoholic/nonalcoholic fatty liver disease
(ALD/NAFLD), in whom heterozygous Pi*Z presence greatly
increased the odds to harbor cirrhosis.8,9 These data were
further strengthened by a large genome-wide association
study, where the Pi*Z variant emerged as the variant
conferring the highest odds ratio (OR) for ALD-/NAFLD-
related cirrhosis,10 while well-known variants in PNPLA3
(rs738409) or TM6SF2 (rs58542926) were either not
significantly associated with ALD/NAFLD-related cirrhosis
or displayed lower odds. Finally, Pi*Z has also been linked to
clinically significant portal hypertension in chronic liver
diseases.11
Despite this unambiguous evidence, the importance and
natural history of the Pi*MZ genotype in the generalpopulation as well as factors promoting liver disease
development in Pi*MZ subjects remain to be defined.
Moreover, the histological and biochemical consequences of
Pi*MZ carriage have not been systematically analyzed. This
is of particular importance to guide the counseling of Pi*MZ
individuals, who in most cases do not display any hepatic
comorbidity. Therefore, we prospectively recruited the
hitherto largest, multinational cohort of genetically diag-
nosed Pi*MZ individuals without previously known liver
disease and assessed their liver phenotypes compared with
Pi*ZZ subjects and noncarriers. In addition to this nonin-
vasive evaluation, we collected liver specimens and con-
ducted a comprehensive and systematic histological,
immunohistochemical, and biochemical evaluation. Finally,
we compared liver transaminases in a large population-
based cohort of Pi*MZ subjects, Pi*ZZ individuals, and
noncarriers. The ultimate goal of our study was to define the
clinical, histological, and biochemical phenotype of Pi*MZ
subjects needed for evidence-based patient management
and counseling.
Methods
Prospectively Recruited Pi*MZ Subjects, Pi*ZZ
Individuals, and Pi*Z Noncarriers (Cohort 1)
Recruitment of European alpha-1 liver
cohort. The studied populations were selected from an
ongoing, multicenter, patient registry on AATD-related liver
disease with intended prospective and longitudinal follow-up
(“European Alpha-1 Liver Cohort”; inclusion and exclusion
criteria are listed later in this article). To establish this Euro-
pean AATD registry, subjects with known or presumed AATD
were recruited at multiple sites across Europe via following
approaches: (1) cooperation with established AATD networks,
(2) cooperation with rare liver disease networks, and (3) a
broad awareness campaign.
(1) In all participating countries, we cooperated with national
and global patient advocacy groups, lung-centered AATD
registries, as well as respiratory specialists with a
particular interest in AATD. Hence, many subjects with
known or presumed AATD were recruited as the afore-
mentioned institutions informed their patients about our
European liver-centered AATD registry, that offered free
examinations in every participating country.
(2) The European commission started a campaign in 2016
to establish Europe-wide networks of health care pro-
viders for rare diseases. Subsequently, the European
Reference Network (ERN) for hepatological diseases
(ERN Rare-Liver; www.rare-liver.eu) was established
and the University Hospital Aachen became the coor-
dinating center for AATD-related liver disease. In
addition, the European Association for the Study of the
Liver provides registry grants for establishing Europe-
wide consortia groups, and in 2017 the University
Hospital Aachen became the coordinating center for
AATD-related liver disease. Within these networks,
patients with known or presumed AATD were referred
from other health care providers to our study group or
patients consulted us directly.








(3) The awareness campaigns were composed of (a) an
AATD liver-related Web site (www.alpha1-liver.eu), (b)
a telephone hotline for patients and physicians, (c) a
presence on social media, (d) talks at patient meetings,
(e) regular contributions to patient-centred periodicals
and patient-centred Web sites, (f) information flyer
handed out to patients on AAT augmentation therapy
for their lung disease, and (g) presentations for physi-
cians caring for patients with AATD.
Non-carriers had been recruited from genetically unrelated
household members of subjects with an established diagnosis of
AATD (33.5%) or as volunteers in liver education campaigns
(66.5%). These campaigns were organized by the University
Hospital Aachen (Germany) andwere announced via local media
to provide a free liver examination for the general population.
Study population and definition of sub-
cohorts. This study population represents a cross-section of
the baseline examinations of the European Alpha-1 Liver
Cohort. All participants of this study population were pro-
spectively recruited from April 1, 2015, to May 1, 2019, and
fulfilled the study-specific inclusion and exclusion criteria
(Figure 1A). In total, 1012 adults of self-reported European
ancestry were recruited in the same manner from 11 European
countries (Austria, Belgium, Czech Republic, Denmark, Ger-
many, Italy, Poland, Portugal, Spain, Switzerland, and the
Netherlands). The inclusion criteria were (1) age 18 years, (2)
no known pregnancy, and (3) the ability to provide a written
informed consent. The main exclusion criteria were (1) the
presence of known liver disease; (2) the presence of concomi-
tant, yet unknown, liver disease picked up during our system-
atic workup (see supplement for details); (3) repeatedly
elevated liver enzymes in medical history; (4) nonvalid
assessment of liver stiffness using vibration-controlled tran-
sient elastography (TE/VCTE; FibroScan, Echosens, Paris,
France); (5) presence of confounders of reliable TE assessment
(eg, nonfasting or cholestasis); or (6) non-European descent.
Pi*ZZ subjects (n ¼ 309) were defined as individuals with
homozygous carriage of the SERPINA1 “Pi*Z” variant
(rs28929474, also known as p.E342K or Glu342Lys), that is,
they had the Pi*ZZ genotype. A major part of this subcohort was
described previously.4 To allow an optimal comparison with
the studied subcohorts, only Pi*ZZ individuals without current
AAT augmentation therapy were included; 48% of the pre-
sented subcohort was recruited in Germany.
Pi*MZ subjects (n ¼ 419) were defined as individuals with
heterozygous carriage of the “Pi*Z” variant without Pi*S (rs17580)
carriage, that is, they had the Pi*MZ genotype. Although most
Pi*ZZ individuals had a previously established diagnosis of AATD,4
most Pi*MZ individuals did not, as they usually neither develop
liver-related nor lung-related symptoms. Indeed, most Pi*MZ
subjects had a family member with an established AATD diagnosis
but had not themselves been genotyped until recruitment into our
registry. Only participants with a proven Pi*MZ genotype
regardless of the AAT serum level were included. 74% of Pi*MZ
subjects were recruited in Germany.
Non-carriers (n ¼ 284) were defined as individuals without
signs of AATD. In all participants, the AAT serum level was
determined by nephelometry and genotyping for the 2 most
relevant mutations of SERPINA1 (ie, the “Pi*Z” variant and the
“Pi*S” variant) was carried out as described.4 Whenever
considered appropriate, the samples were additionally sent tothe corresponding national AAT reference laboratory for
further phenotyping via isoelectric focusing as well as for
further genetic analyses according to established recommen-
dations.12 Hence, noncarriers had a normal AAT serum level
(>110 mg/dL) and were neither carriers of the Pi*Z nor the
Pi*S variant. A major part of this subcohort was described
previously4; 90% of the noncarrier subcohort at hand was
recruited in Germany.
Assessment of liver disease and ethical state-
ment. Details are given in the supplement.
Analysis in the Population-based UK Biobank
(Cohort 2)
A total of 487,831 participants were genotyped for both the
Pi*Z and Pi*S mutation; 43,330 participants were excluded
because of Pi*S carriage (either heterozygous/homozygous or
compound heterozygosity with Pi*Z). Further details are given
in the Supplement.
Histological Analysis of Liver Biopsies (Cohort 3)
During the course of the study, we collected percutaneous
liver biopsies from a total of 84 Pi*MZ and 35 Pi*ZZ individuals.
Further details are given in the Supplement.
Biochemical Analysis of Liver Specimens (Cohort 4)
Tissue samples for protein analyses were obtained from
Pi*MZ (n ¼ 6) and Pi*ZZ subjects (n ¼ 7) as well as noncarriers
(n ¼ 7) who underwent clinically indicated liver biopsies or
liver resection (Figure 1C). Further details are given in the
Supplement.
Statistical Analysis
Details are given in the Supplement.
Results
Liver-related Parameters in Pi*MZ Subjects
(Cohort 1)
We analyzed the liver phenotype of 419 Pi*MZ subjects,
309 Pi*ZZ individuals, as well as 284 Pi*Z noncarriers, all
without previously known or concomitant liver disease
(Figure 1A). All 3 groups showed a comparable sex distri-
bution and similar rates of diabetes mellitus (Table 1).
Pi*MZ subjects were younger than the other 2 groups,
whereas Pi*ZZ individuals displayed the lowest body mass
indices (BMI) (Table 1). Relevant alcohol consumption (12–
40 g/d for women / 24–60 g/d for men) was rare in all 3
groups but more frequent in noncarriers (Table 1). As ex-
pected, Pi*MZ subjects showed intermediate AAT serum
levels (87 ± 20 mg/dL vs 139 ± 27 mg/dL in noncarriers vs
30 ± 25 mg/dL in Pi*ZZ, all P < .0001, Table 1, Figure 2A).
The previously proposed cutoff AAT level of 110 mg/dL
differentiated well between AATD subjects (Pi*MZ/Pi*ZZ)
and noncarriers (positive likelihood ratio 9.7, negative
likelihood ratio 0.1).
Alanine aminotransferase (ALT), bilirubin, and alkaline
phosphatase (ALP) levels did not show major differences
among genotypes. Mean aspartate aminotransferase (AST)
Figure 1.Overview of analyzed subpopulations. (A) Cohort 1:
Prospectively recruited individuals as part of the “European
Alpha-1 Liver” registry cohort. (B) Cohort 2: Population-based
study analyzing participants with Pi*Z but without Pi*S car-
riage. (C) Cohort 3: Histologic analysis of Pi*MZ and Pi*ZZ
individuals with an indication for liver biopsy. (D) Cohort 4:
Biochemical analysis of liver specimen. Pi*Z, most relevant
mutation of SERPINA1; Pi*S, second most relevant mutation
of SERPINA1; Pi*MZ, heterozygosity for the Pi*Z variant;
Pi*ZZ, homozygosity for the Pi*Z variant.
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LIVERvalues were higher in Pi*ZZ vs Pi*MZ participants but were
comparable between noncarriers and Pi*MZ individuals
(Supplementary Table 1; Figure 2C). Gamma-glutamyl
transferase (GGT) was the only parameter that clearly
differed among the 3 genotypes, that is, the values were the
lowest in noncarriers and highest in Pi*ZZ subjects
(Supplementary Table 1; Figure 2D). Surrogate markers for
advanced chronic liver disease such as platelet count, al-
bumin, and International Normalized Ratio were within
normal limits in most study participants (Supplementary
Table 1). In line with previous observations, Pi*ZZ sub-
jects had lower triglyceride levels than both noncarriers and
Pi*MZ individuals (Supplementary Table 1).To further account for the age difference between the
groups, we separately assessed all parameters in partici-
pants who were 50 years old. Among them, Pi*MZ in-
dividuals displayed higher ALT, AST, GGT, and ALP levels
than noncarriers (Supplementary Table 2). Compared with
older Pi*MZ subjects, older Pi*ZZ individuals had elevated
AST, GGT, and bilirubin levels, whereas platelets, and tri-
glyceride values were lower (Supplementary Table 2).
Liver Fibrosis and Steatosis in Prospectively
Recruited Pi*MZ Subjects (Cohort 1)
To noninvasively determine the degree of liver fibrosis
and steatosis, all participants from the registry cohort were
evaluated with TE. Pi*MZ individuals had intermediate LSM
values, that is, LSM values were higher than in noncarriers
(5.5 ± 6.0 kPa vs 4.5 ± 1.3 kPa, P ¼ .007), but lower than in
Pi*ZZ subjects (5.5 ± 6.0 kPa vs 7.0 ± 6.9 kPa; P ¼ .004,
Table 1; Figure 2E). Ten percent of Pi*MZ individuals
showed LSM values 7.1 kPa (ie, values suggesting fibrosis
stage of at least 2) compared with 4% of noncarriers
(adjusted OR ¼ 4.8 [2.0–11.8], P ¼ .001; Table 1) and 25%
of Pi*ZZ subjects (adjusted OR ¼ 0.3 [0.1–0.9], P < .0001;
Table 1). The difference between Pi*ZZ, Pi*MZ, and non-
carriers was even more pronounced for those with LSM 10
kPa suggesting at least fibrosis stage 3 (11% vs 4% vs 1%;
all P < .01; Table 1). Notably, the differences in LSM
remained significant when only participants 50 years old
were considered (Supplementary Table 2). To further
corroborate the association of increased LSM in Pi*MZ
subjects, we constructed multiple logistic regression models
accounting for potential confounders. In all of them, Pi*MZ
individuals had significantly higher odds for LSM ,7.1 kPa
as well as LSM 10 kPa than noncarriers (Supplementary
Table 3).
To determine cofactors associated with liver fibrosis, we
compared Pi*MZ individuals with Pi*ZZ subjects who both
had LSM 7.1 kPa. Although largely the same risk factors
were identified in both groups (ie, higher age, male sex, and
higher BMI), Pi*MZ individuals with LSM 7.1 kPa were
clearly more obese or diabetic than their Pi*ZZ counterparts
(Supplementary Table 4).4
The simultaneously assessed controlled attenuation
parameter (CAP), which is an established surrogate of he-
patic steatosis, showed higher mean values in Pi*ZZ in-
dividuals than in Pi*MZ subjects (258 ± 59 dB/m vs 245 ±
61 dB/m, P < .0001), but no difference between Pi*MZ
subjects and noncarriers (Table 1; Figure 2F).
Factors Associated With Significant Liver Fibrosis
in Pi*MZ Subjects (Cohort 1)
To identify the demographic and laboratory parame-
ters associated with significant liver fibrosis in Pi*MZ
participants, we compared the subgroups with LSM <7.1
and 7.1 kPa. Age 50 years (OR ¼ 2.3 [1.2–4.5]), BMI
30 kg/m2 (OR ¼ 3.8 [1.9–7.5]), and CAP 248 dB/m
suggesting steatosis (OR ¼ 3.1 [1.4–6.5]) conferred higher
odds of having LSM 7.1 kPa (Supplementary Table 5;
Supplementary Figure 1). Notably, diabetic Pi*MZ

























Age (y) 51±15 45±16 50±15 <.0001 <.0001
Women (%) 52 56 49 .30 .054
BMI (kg/m2) 26.0±5.2 26.0±4.6 24.9±4.5 .94 .002
Mean alcohol consumption (g/d) 7.1±9.7 4.4±.6.8 4.2±7.3 <.0001 .77
AAT serum level (mg/dL) 139±27 87±20 30±25 <.0001 <.0001 <.0001 <.0001
Modifiable risk factors
BMI 30 kg/m2 (%) 17 18 10 .77 .002
Diabetes mellitus (%) 5 4 4 .66 .83
Relevant alcohol intakea (%) 13 7 7 .007 .95
Liver status
Liver stiffness (kPa) 4.5±1.3 5.5±6.0 7.0±6.9 .007 .005 .002 .0004
Liver stiffness 7.1 kPa (%) 4 10 25 .005 .002 <.0001 <.0001
Liver stiffness 10.0 kPa (%) 1 4 11 .005 .010 .0001 .001
CAP (dB/m) 244±60 245±61 258±59 .84 .094 .008 .0002
CAP 248 dB/m (%) 49 49 57 .97 .20 .051 .020
CAP 280 dB/m (%) 27 29 33 .52 .13 .37 .14
NOTE. Quantitative measures are expressed as means and standard deviations or as relative frequencies (%). The cutoffs for
liver stiffness were selected based on etiology-unspecific recommendations, that is, 7.1 kPa suggesting the presence of
significant fibrosis (fibrosis stage 2) and 10.0 kPa suggesting the presence of advanced fibrosis (fibrosis stage 3). The
cutoffs for controlled attenuation parameter (CAP) were selected based on etiology-unspecific recommendations, that is,
248 dB/m suggesting the presence of steatosis (steatosis grade 1) and 280 dB/m suggesting the presence of severe
steatosis (steatosis grade ¼3). All multivariable analyses were adjusted for age, sex, BMI, diabetes, and mean alcohol
consumption.
aAlcohol intake >12 g/d women, >24 g/d men (Individuals with alcohol consumption >40 g/d for females or >60 g/d for males
had been excluded a priori). P values <.05 are indicated in bold font.








individuals displayed particularly high odds to have LSM
7.1 kPa (OR ¼ 8.1 [2.9–23.2]). Interestingly, male sex did
not confer a significantly increased risk of LSM 7.1 kPa
(OR ¼ 1.8 [1.0–3.4] (Supplementary Figure 1). Among
laboratory parameters, elevated GGT (OR ¼ 2.6 [1.2–5.3])
and reduced platelets (OR ¼ 4.2 [1.4–12.6]) were the
parameters most clearly associating with LSM 7.1 kPa
(Supplementary Table 5). Basically the same risk factors
and ORs were seen for LSM 10 kPa (Supplementary
Figure 1).
To further study the importance of obesity as the major
modifiable risk factor, we compared obese and nonobese
individuals (Supplementary Figure 2). Although obese
noncarriers displayed higher LSM and GGT values than their
nonobese counterparts, the obese Pi*MZ subjects had the
highest values of all subgroups. In particular, obese Pi*MZ
subjects had approximately 4 times the odds of LSM 7.1
kPa compared with nonobese Pi*MZ individuals (unad-
justed OR ¼ 3.8 [1.9–7.5]; Supplementary Table 5). To
further corroborate this finding, we included Pi*MZ geno-
type carriage, obesity, and their interaction term (ie,
Pi*MZ  obesity) in a logistic regression model on the status
of LSM 7.1 kPa. Although both Pi*MZ and obesity made
significant contributions in the main effects model (P ¼ .006
and P < .0001, respectively), additionally including the
interaction term (Pi*MZ x obesity) yielded a nonsignificanttesting result (P ¼ .33). This indicated independent and
additive contributions (on the logit scale) by both Pi*MZ and
obesity. The same analysis for BMI (continuous) instead of
obesity (BMI dichotomized by 30 kg/m2) revealed compa-
rable results.
With regard to serum GGT, the most prominently
elevated liver-related blood parameter in Pi*MZ subjects,
we compared Pi*MZ individuals with GGT within and above
the sex-specific upper limit of normal (ULN)
(Supplementary Table 6). Elevated GGT was associated with
obesity; elevated ALT, AST, ALP, and triglycerides; as well as
increased LSM and CAP. To further corroborate the higher
odds of Pi*MZ subjects to display increased GGT, we con-
structed multiple logistic regression models accounting for
potential confounders. In all of them, Pi*MZ individuals had
significantly higher odds for elevated GGT than noncarriers
(Supplementary Table 7).
Finally, to facilitate patient counseling, we determined
the frequency of LSM 7.1 kPa in clinically relevant
Pi*MZ subpopulations (Figure 3). Among the analyzed
parameters, the presence of diabetes and decreased
platelet counts ( < 150 G/L) conferred >20% chance to
have LSM 7.1 kPa, whereas male sex as well as elevated
AST, ALT, or GGT levels were associated with a similarly
high risk only in Pi*MZ individuals who were 50 years
old (Figure 3).
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Figure 3. Rate of Pi*MZ individuals with significant liver fibrosis (LSM 7.1 kPa) among the highlighted subpopulations (Cohort
1). Relative frequencies (%) are shown and visualized by a color coding (right). DM, diabetes mellitus; Plt, platelets.








Liver Transaminases in the Population-based UK
Biobank (Cohort 2)
To validate the findings from the cross-sectional analysis
from the aforementioned registry cohort, and to provide
largely unbiased population-based data, we turned to the
UK biobank cohort (Figure 1B). Pi*MZ individuals were
older and less likely to have diabetes compared with non-
carriers (Table 2). To account for these differences, we
applied multivariable analyses adjusting for age, sex, BMI,
presence of diabetes, and mean alcohol consumption.
Compared with noncarriers, Pi*MZ subjects had higher ALT
serum levels (58.9 ± 32.1 vs 56.3 ± 33.2 (% of ULN),
adjusted P ¼ 1.6*10–30) and more frequently ALT levels
above the ULN (7.5% vs 6.6%, adjusted P ¼ 9.1*10–9;
Table 2). Likely due to the low numbers of Pi*ZZ subjects,
the differences between Pi*MZ and Pi*ZZ individuals did not
reach statistical significance (Table 2). Regarding serum AST
levels, Pi*MZ subjects had intermediate levels compared
with noncarriers and Pi*ZZ individuals (Pi*MZ vs non-
carriers: 65.3 ± 24.3 vs 63.8 ± 26.7 (% of ULN), adjusted
P ¼ 1.9*10–14; Pi*MZ vs Pi*ZZ: 65.3 ± 24.3 vs 77.0 ± 29.0
(% of ULN), adjusted P ¼ 4.0*10–10; Table 2). Accordingly,
Pi*MZ individuals had an intermediate proportion of in-
dividuals with serum AST above the ULN (Pi*MZ vs non-
carriers: 5.2% vs 4.6%, adjusted P ¼ 1.9*104; Pi*MZ vs
Pi*ZZ; 5.2% vs 15.9%, adjusted P ¼ 1.6*10–8; Table 2).=
Figure 2. AAT concentrations and liver-related parameters in su
for the Pi*Z variant of SERPINA1 compared with noncarriers (C
and 284 noncarriers were analyzed. The shown P values were ad
consumption. (A) Scatter plot of the absolute serum AAT concen
which was previously suggested to discriminate between Pi*MZ
ALT, AST, and GGT levels, each normalized to the sex-specific U
measurements determined by TE. The dotted lines represent
(suggestive of fibrosis stage 2), 10.0 kPa (suggestive of fibros
Scatter plot of CAP, a surrogate parameter of liver steatosis dete
unspecific cutoff levels44: 248 dB/m (suggestive of steatosis gra
dB/m (suggestive of steatosis grade 3).Histological and Biochemical Phenotype of
Pi*MZ Livers (Cohorts 3 and 4)
To characterize the histological phenotype of Pi*MZ
status, we compared 84 liver biopsies from Pi*MZ with 35
biopsies from Pi*ZZ individuals (Figure 1C). Although the
presence of comorbidities other than NAFLD was excluded
by systematic workup, we decided to keep individuals with
NAFLD in the analysis as NAFLD is a widespread entity seen
in a substantial part of the Caucasian population. Definite
nonalcoholic steatohepatitis (defined as NAS score 5) was
rare in both groups (Table 3). Pi*MZ subjects had higher
BMI (31.4 ± 6.5 vs 25.9 ± 7.3 kg/m2; P < .0001) and a
higher prevalence of diabetes (31% vs 3%; P ¼ .001),
whereas Pi*ZZ individuals were more frequently male (83%
vs 59%, P ¼ .013, Table 3). Compared with the prospec-
tively recruited Pi*MZ participants (cohort 1), biopsied
Pi*MZ individuals (cohort 3) were older (55 ± 16 vs 45 ± 16
years; P < .0001), more frequently male (56% vs 44%; P <
.0001), and had higher BMI (31.4 ± 6.5 vs 26.0 ± 4.6 kg/m2;
P < .0001; Supplementary Table 8).
Histological assessment revealed no differences in stea-
tosis and inflammation, whereas Pi*MZ biopsies showed
lower fibrosis stages (2.2 ± 1.3 vs 2.9 ± 1.0, P ¼ .007) and
lower proportion of perisinusoidal fibrosis (69.1% vs
97.1%, P ¼ .002). Hematoxylin and eosin staining, as the
routine histological assessment method, revealed inclusion
bodies in >50% of Pi*ZZ individuals but only in 10.7% ofbjects heterozygous (Pi*MZ/MZ) and homozygous (Pi*ZZ/ZZ)
ohort 1). A total of 419 Pi*MZ individuals, 309 Pi*ZZ subjects,
justed for age, sex, BMI, diabetes mellitus, and mean alcohol
trations. The dotted line represents the 110 mg/dL cutoff level,
individuals and noncarriers.42,43 (B–D) Scatter plots of serum
LN, marked with a dotted line. (E) Scatter plot of liver stiffness
the following etiology-unspecific cutoff levels4,15: 7.1 kPa
is stage 3), and 13.0 kPa (suggestive of fibrosis stage 4). F)
rmined by TE. The dotted lines indicate the following etiology-
de 1), 268 dB/m (suggestive of steatosis grade 2), and 280
Table 2.Characteristics of Individuals From the Population-based UK Biobank Who Neither Carry the Pi*Z Nor the Pi*S Variant









P value NC vs
MZ
(univariable)
P value MZ vs
ZZ
(univariable)
P value NC vs
MZ
(multivariable)
P value MZ vs
ZZ
(multivariable)
Age (y) 56.5±8.1 56.9±8.1 56.4±7.9 4.5*10–10 .17
Men (%) 46 45 52 .31 .13
Diabetes mellitus (%) 5 4 2 2.8*10–7 .58
BMI (kg/m2) 27.4±4.8 27.3±4.7 26.8±4.9 2.2*10–5 .27
Alcohol (units/d) 1.28±1.60 1.32±1.41 1.15±0.86 .49 .65
ALT (% of ULN) 56.3±33.2 58.9±32.1 62.9±25.9 1.2*10–22 .16 1.6*10–30 .077
ALT ULN (%) a 6.6 7.5 11.4 3.0*10–6 .09 9.1*10–9 .051
AST (% of ULN) 63.8±26.7 65.3±24.3 77.0±29.0 7.2*10–13 4.0*10–8 1.9*10–14 4.0*10–10
AST ULN (%) b 4.6 5.2 15.9 .001 2.8*10–8 1.9*10–4 1.6*10–8
NOTE. Quantitative measures are expressed as means and standard deviations or as relative frequencies (%).
aMZ vs noncarriers: Unadjusted OR ¼ 1.129 [1.054–1.210], adjusted OR ¼ 1.189 [1.121–1.261].
bMZ vs noncarriers: Unadjusted OR ¼ 1.148 [1.083–1.216], adjusted OR ¼ 1.142 [1.065–1.225]; MZ vs ZZ: Unadjusted OR ¼
0.286 [0.178–0.459], adjusted OR ¼ 0.250 [0.154–0.404]. P values <.05 are indicated in bold font. One unit equals 8 g alcohol.
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D–positive inclusions were detected in all but 2 Pi*ZZ in-
dividuals, but only in 40.5% of Pi*MZ subjects (P < .0001,
Table 3, Figure 4A and B). Immunohistochemistry (IHC)
constituted the most sensitive method for detection of AAT
inclusions (Figure 4A) and visualized aggregates in all but 1
Pi*ZZ individual (97%) and in 63% of Pi*MZ subjects (P <
.0001, Table 3, Figure 4A and B). When using IHC, 74% of
Pi*ZZ individuals showed inclusions in more than 20 he-
patocytes per field, whereas only 37% of Pi*MZ subjects
displayed such abundant aggregates (P < .0001, Table 3).
Accordingly, Pi*MZ individuals had lower mean inclusion
scores (1.6 ± 1.3 vs 2.6 ± 0.8, P < .0001, Table 3).
Because data from Pi*ZZ subjects indicate that the
amount of AAT inclusions increases during, or may even
promote, the progression of liver disease,5 we assessed the
abundance of inclusions throughout different fibrosis stages.
In IHC analysis, all cirrhotic Pi*MZ individuals displayed
many inclusions, whereas most noncirrhotic Pi*MZ subjects
had no or only rare inclusions. Overall, in Pi*MZ individuals,
higher fibrosis stages were clearly associated with higher
inclusions scores (Figure 4C). Although the differences were
less obvious in Pi*ZZ subjects, most Pi*ZZ individuals with
no or mild fibrosis had no or only few inclusions, whereas
most Pi*ZZ subjects with significant liver fibrosis/cirrhosis
had many AAT aggregates (Figure 4C). With regard to other
demographic parameters and/or histological features, AAT
inclusions were more numerous in 50-year-old Pi*MZ in-
dividuals, whereas no obvious relationship with sex, BMI,
and presence of steatosis or inflammation was noted
(Supplementary Figure 3).
To quantify hepatic AAT levels, we performed immuno-
blotting of total tissue lysates (Figure 1D). Notably, we did
not observe a significant accumulation of AAT in Pi*MZ in-
dividuals, whereas Pi*ZZ subjects displayed markedly
elevated hepatic AAT levels (Figure 4D). Furthermore, no
insoluble AAT was seen in noncarriers, whereas the
amounts of insoluble AAT strongly varied among the Pi*MZindividuals. Although some of them did not show any
insoluble AAT, others had levels comparable or even higher
than the amount of soluble AAT (Figure 4E).
Collectively, our data indicate that the presence of AAT
inclusions cannot be used for histological diagnosis of Pi*MZ
subjects and that the amounts of inclusions strongly differ
between both the individuals and the disease stages.Discussion
Our study represents the first systematic evaluation of
liver disease burden in Pi*MZ individuals. By combining the
multinational registry cohort and the population-based
cohort, we were able to demonstrate that Pi*MZ subjects
display an intermediate liver phenotype compared with
noncarriers of Pi*Z and Pi*S as well as Pi*ZZ individuals.
Among serum levels of liver enzymes in the registry
cohort, GGT was most strongly elevated and significantly
higher in Pi*MZ individuals compared with noncarriers. This
is not surprising because GGT also constitutes the most
commonly elevated liver enzyme in Pi*ZZ subjects4; how-
ever, only borderline or no difference was seen in AST and
ALT levels. This was unexpected, given that Pi*MZ subjects
harbored substantially higher AST/ALT levels than non-
carriers in a large genome-wide study10 and another
genome-wide study confirmed the higher ALT values.13 To
clarify this discrepancy, we turned to a large population-
based cohort and found elevated AST and ALT values in
Pi*MZ individuals compared with noncarriers. The
limited size of our registry cohort, the different recruit-
ment strategy, the exclusion of individuals with repeat-
edly elevated transaminases, and/or the
overrepresentation of younger and nonobese individuals
may explain the fact, that no consistent differences in
transaminase levels were seen.
A particular strength of our registry cohort was the
noninvasive evaluation of liver fibrosis via LSM in all par-
ticipants. Although LSM and CAP using TE was not validated
Table 3.Characteristics of Pi*MZ and Pi*ZZ Individuals Who Received a Liver Biopsy (Cohort 3)






Age (y) 55±16 53±12 .44
Women (%) 44 17 .006
BMI (kg/m2) 31.4±6.5 25.9±7.3 <.0001
Mean alcohol consumption (g/d) 5.1±10.3 4.1±6.6 .63
AAT augmentation therapy (%) N/A 34 N/A
Modifiable risk factors
BMI 30 kg/m2 (%) 61 24 <.0001
Diabetes mellitus (%) 31 3 .001
Relevant alcohol intakea (%) 5 3 .32
Steatosis
Steatosis grade 1.4±0.9 1.2±0.9 .15 .78
Steatosis grade 0 (%) 15.5 25.7 .19 .96
Steatosis grade 1 (%) 40.5 34.3 .53 .73
Steatosis grade 2 (%) 28.5 37.1 .36 .17
Steatosis grade 3 (%) 15.5 2.9 .052 .15
Fibrosis
Fibrosis stage (Kleiner) 2.2± 1.3 2.9±1.0 .007 <.001
Fibrosis stage 0 13.1 2.9 .093 .007
Fibrosis stage 1 13.1 5.7 .24 .59
Fibrosis stage 2 28.6 20.0 .33 .40
Fibrosis stage 3 28.6 42.9 .13 .14
Fibrosis stage 4 16.7 28.6 .14 .13
Perisinusoidal fibrosis (%) 69.1 97.1 .002 <.0001
Inflammation
Lobular inflammation (%) 40.5 41.2 .94 .95
Portal inflammation (%) 72.8 61.8 .24 .55
Hepatocyte ballooning (%) 33.3 11.8 .049 .43
Inflammatory foci (%) 41.9 14.7 .007 .10
NAS score 2.4±1.7 1.5±1.2 .004 .32
0–1 (%) 35.7 55.9 .031 .30
2–4 (%) 54.8 41.2 .14 .28
5 (%) 9.5 2.9 .21 .82
AATD-related findings
Inclusion bodies in HE (%) 10.7 57.1 <.0001 <.0001
Inclusion bodies in PAS-D (%) 40.5 94.3 <.0001 <.0001
Inclusion bodies in immunohistochemistry (%) 63.1 97.1 <.0001 <.0001
Inclusion bodies in >5 hepatocytes (%) 54.7 85.7 <.0001 <.0001
Inclusion bodies in >20 hepatocytes (%) 36.9 74.3 <.0001 <.0001
Inclusion body score 1.6±1.3 2.6±0.8 <.0001 <.0001
NOTE. Quantitative measures are expressed as means and standard deviations or as relative frequencies (%). Fibrosis stage
and steatosis grade are based on Kleiner scoring system. Disease activity was assessed with Nonalcoholic Fatty Liver Disease
Activity Score (NAS). The abundance of inclusion bodies was evaluated as described5 and was based on appearance in
immunohistochemistry staining with a specific antibody for mutated Pi*Z protein.41 All multivariable analyses were adjusted for
age, sex, BMI, diabetes, and mean alcohol consumption.
HE, hematoxylin and eosin staining; N/A, not applicable.
aAlcohol intake >12 g/d women, >24 g/d men (Individuals with alcohol consumption >40 g/d for females or >60 g/d for males
had been excluded a priori). P values <.05 are indicated in bold font.








in Pi*MZ subjects per se, TE was recently validated in Pi*ZZ
subjects5,11,14 and was extensively validated in both the
general population as well as various liver disease
entities.15–18 LSM demonstrated 5- and 9-times increased
odds for significant and advanced liver fibrosis in Pi*MZ
individuals vs noncarriers, respectively (Supplementary
Table 3). The latter OR is comparable with the reported
odds of Pi*MZ subjects to develop cirrhosis when sufferingfrom cystic fibrosis, ALD, or NAFLD.8,9 In contrast, other
studies reported a lower, but still significant, enrichment of
Pi*MZ individuals in patients with ALD/NAFLD-associated
cirrhosis or clinically significant portal hypertension as
well as in patients who underwent liver
transplantation.10,11,19
Although the Pi*MZ status constitutes an undisputed
risk factor for significant liver fibrosis and although a
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growing body of evidence convincingly shows that Pi*MZ
individuals are susceptible to developing liver fibrosis in
coexisting liver disease (“second hit”), understanding the
additional factors is of utmost importance. To delineate
them, we focused on individuals without concomitant liver
disease. Comparable to other entities of liver disease, the
most prominent risk factors associating with LSM 7.1
kPa in Pi*MZ subjects were presence of obesity and dia-
betes mellitus. Moreover, age 50 years was a comparably
weak disease modifier. However the association was not
unexpected, because older Pi*ZZ subjects have a higher
risk to suffer advanced liver fibrosis than younger Pi*ZZ
individuals.4,20,21 Although a rising prevalence of liver
fibrosis in the aging population is well documented,22,23
aging may be particularly applicable to genetic liver dis-
ease, where the duration of the exposure to the etiologic
factor (ie, misfolded AAT in hepatocytes) increases
steadily with age. In addition, aging entails an increased
proteotoxic stress7,24 and decreased autophagic capacity25
and because of that, might be of particular relevance in
AATD.24 In that respect, the amount of AAT inclusions was
higher in 50 year-old Pi*MZ individuals (Supplementary
Figure 3), whereas inclusions were rarely seen in neonatal
AATD-related liver disease.2 Obesity was not only a
comparably strong, but also an independent and additive
risk factor for LSM 7.1 kPa in Pi*MZ subjects. This
disease-promoting role of obesity is not surprising,
because it is known to promote liver fibrogenesis in other
etiologies and because it has been shown to amplify the
effect of other genetic variants.26,27 Moreover, obesity was
also associated with advanced liver fibrosis in individuals
with the Pi*ZZ genotype.4 However, compared with Pi*ZZ
individuals, Pi*MZ subjects appear to need a “stronger”
metabolic second hit to develop significant liver fibrosis
(Supplementary Table 4). Finally, among the described
contributing factors, the presence of diabetes conferred 8
times higher odds to display LSM 7.1 kPa
(Supplementary Figure 1). These results are reminiscent of
the situation in Pi*ZZ individuals, where the presence of
diabetes also strongly associates with significant liver
fibrosis.5 Although the exact relationship between diabetes
and AATD remains to be determined, insulin resistance
results in an increased lipolysis that likely augments the
endoplasmic reticulum stress occurring in AATD livers.28
In terms of patient and family counseling regarding
modifiable risk factors, Pi*MZ individuals should be
advised that obesity and insulin resistance/diabetes=
Figure 4. Comparison of the histological and biochemical featur
of the Pi*Z variant (Cohorts 3 and 4). (A) Histological appearance
were stained with hematoxylin and eosin (H&E), PAS-D, or with
PINA1.41 (B) Rate of detection of inclusion bodies in Pi*MZ and
previously. (C) Amounts of inclusion bodies per field in biopsy sa
based on IHC. The abundance of inclusion bodies was scored
inclusions in up to 5 cells; few, inclusion bodies in 5 to 20 cells
levels were assessed by immunoblotting in total lysates obtaine
noncarriers. GAPDH was used as a loading control. (E) AAT solu
samples from Pi*MZ individuals and noncarriers. GAPDH and
insoluble pools, respectively. Univariate P values are shown inmarkedly increase their risk to develop significant liver
disease.
Besides an identification of disease-promoting factors,
we also assessed routine laboratory parameters, which
might be useful to facilitate the clinical management of
this large patient group. Among them, elevated GGT levels
and decreased platelet counts were particularly indicative
of LSM 7.1 kPa (Supplementary Figure 1). This is not
surprising because GGT has been shown to predict the
existence of significant liver fibrosis in Pi*ZZ subjects.4,5
As a likely underlying mechanism, GGT is an established
marker of metabolic liver disease and plays an important
role in defense against oxidative stress.29,30 The usefulness
of platelet count is well in line with its ability to predict
liver fibrosis and portal hypertension in general and sig-
nificant liver fibrosis in Pi*ZZ subjects in particular.4,31
To better understand the consequences of Pi*MZ sta-
tus, we performed a detailed histological, immunohisto-
chemical, and biochemical analysis. We demonstrated that
occurrence of AAT aggregates is not an obligate/manda-
tory feature of Pi*MZ genotype and that in contrast to
Pi*ZZ individuals, it is seen only in a minority of Pi*MZ
subjects with no or mild liver fibrosis.5 Hence, PAS-D or
Pi*Z IHC staining neither allows histological diagnosis of
Pi*MZ individuals nor is it useful to discriminate Pi*MZ
from Pi*ZZ subjects. This finding is important both for
scientific and routine clinical evaluation of these in-
dividuals as many centers solely relied on liver histology
yet. For example, multiple studies used the presence of
AAT globules as a method to screen for Pi*MZ status.32–35
Such studies likely miss a significant portion of Pi*MZ
individuals and may enrich for heterozygotes with a more
severe liver pathology. Therefore, genetic approaches
(ideally in combination with AAT phenotyping) are rec-
ommended for a reliable detection of Pi*MZ status.
Our histological/biochemical examination revealed
that the amount of accumulated AAT displays strong
interindividual differences but increases with progression
of liver disease. The former finding is reminiscent of the
situation in Pi*ZZ subjects5 and might be, at least in part,
due to interindividual variability in AAT expression and
degradation.2 Given the correlation between the expres-
sion of Pi*Z and the development of liver disease seen in
transgenic mice,36 as well as the fact that Pi*ZZ in-
dividuals with manifest liver disease frequently display a
delayed AAT degradation,37 it is tempting to speculate
that abundant AAT aggregates identify patients at risk fores of heterozygotes (MZ), homozygotes (ZZ), and noncarriers
of AAT aggregates in corresponding liver tissue sections that
IHC using an antibody specific for the Pi*Z variant of SER-
Pi*ZZ subjects when using the staining approaches described
mples of Pi*MZ/Pi*ZZ individuals with different fibrosis stages,
as described by Clark et al5: no, no inclusions visible; rare,
; and many, inclusions in more than 20 cells. (D) AAT protein
d from liver biopsies of Pi*MZ subjects, Pi*ZZ individuals, and
bility in 1% Triton-X containing-buffer was determined in liver
keratin 8 (K8) were used as loading controls for soluble and
all panels.
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tion may be both a sign and a culprit of advancing liver
disease. With regard to the former, SERPINA1 represents a
stress-inducible gene and a stress-mediated increase in
AAT production promoted the development of liver injury
in transgenic mice overexpressing the Pi*Z variant.2,4,38
Therefore, hepatotoxic stress in Pi*MZ subjects with
advanced liver disease may result in a vicious cycle with
elevated Pi*Z production and a consequent aggravation of
liver damage. To support this hypothesis, a recent study
demonstrated that Pi*MZ individuals with cirrhosis were
at increased risk of hepatic decompensation, as compared
with cirrhotic noncarriers.19
A potential limitation is the cross-sectional design of
the multinational registry cohort which cannot deduce
cause-and-effect relationships and cannot fully exclude
selection bias. The only population-based cohort aiming
at Pi*ZZ individuals is from a birth screening program
in w200,000 Swedish newborns: the 87 participants
who remained in the follow-up are now approximately
45 years old,39,40 which is below the typical manifes-
tation age of AATD-related liver disease. Moreover,
despite our broad awareness campaign basically
involving all stakeholders dealing with AATD in-
dividuals, there still is a “hidden” population that we
were unable to account for, as many Pi*MZ individuals
neither develop symptoms nor have a known family
history of AATD (ie, as they remain undetected they do
not hear about our Europe-wide initiative). However,
several analyses accounting for relevant confounders as
well as the observations in the population-based UK
biobank and large genome-wide studies suggest that the
presented observations hold true. Despite that, a vali-
dation of the observed findings in prospective screening
cohorts is warranted.
Another challenging issue in studies analyzing the
natural history of rare genetic variants is the exact
composition of control cohorts. In the registry cohort, the
noncarriers were examined in exactly the same manner as
AATD individuals and were recruited both from the
general population (two-thirds) as well as from unrelated
household members of AATD participants (one-third).
The unrelated household members share unknown envi-
ronmental factors with AATD subjects, which cannot be
accounted for in statistical analyses. Importantly, the re-
sults from the population-based UK biobank (having the
least possibility of selection bias) underline that the
Pi*MZ status is independently associated with higher
serum transaminases.
In summary, our study involving 4 large and multina-
tional cohorts defines the clinical, histological, and
biochemical liver phenotype of adult Pi*MZ subjects as
well as risk factors for significant liver fibrosis. This
comprehensive phenotyping supports the emerging
concept that Pi*MZ individuals are at risk of developing
liver disease, especially in the presence of the discovered
risk factors (eg, obesity and diabetes). This is particularly
relevant, because only a small portion of the studied Pi*MZ
population displays clinically relevant liver disease, but itis indispensable to recognize them. A long-term, prospec-
tive monitoring of Pi*MZ subjects will be necessary to
determine the rate of disease progression and the occur-
rence of complications of advanced chronic liver disease.
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Supplementary Methods
Prospectively Recruited Pi*MZ Subjects, Pi*ZZ
Individuals, and Pi*Z Noncarriers (Cohort 1)
Assessment of Liver Disease. All comers fulfilling
the inclusion criteria have been examined and all exami-
nations (questionnaires, physical examination, blood
collection, and TE) were performed on the same day. Each
participant completed standardized questionnaires (eg,
demographic parameters or concomitant diseases). In all
participants, the presence of a previously existing liver
disease was excluded by a personal interview (eg, no
established diagnosis of chronic liver disease, no repeatedly
elevated liver enzymes, and no history of liver resection or
liver transplant) as well as by physical examination. The
only exception was known NAFLD without histologically
proven nonalcoholic steatohepatitis as NAFLD is a wide-
spread entity seen in a substantial part of Caucasian pop-
ulation and as steatosis is associated with Pi*ZZ-related
liver disease.1 For each participant, drinking habits were
evaluated in a face-to-face conversation, determining the
average weekly number of alcoholic beverages. Conse-
quently, the amount of alcohol consumed per week was
calculated and used for further analysis. Participants with
excessive mean alcohol consumption (>40 g/d women,
>60 g/d men) were excluded (5 Pi*ZZ, 4 Pi*MZ, 1
noncarrier). All participants underwent blood sampling. The
obtained venous blood was centrifuged, aliquoted, and
stored at 80oC. Laboratory workup was performed as
described1 to exclude liver comorbidities. It consisted of (1)
a serologic search for chronic infections with hepatitis B
and C virus (1 Pi*MZ and 2 Pi*ZZ individuals were
excluded); (2) serum ferritin levels and transferrin satura-
tion to screen for the presence of hereditary hemochro-
matosis (1 Pi*ZZ subject with an otherwise unexplained
significant increase in both ferritin [>500 ng/mL] and
transferrin saturation [>45%] was excluded); and (3)
screen for autoimmune hepatitis in individuals with
elevated serum transaminase levels (no exclusions).
TE was used as the most established method for
noninvasive assessment of liver fibrosis and LSM using TE
was recently validated in 2 biopsy-proven cohorts of adult
Pi*ZZ individuals.2,3 TE was performed using the M or XL
probe following established recommendations.4–6 Experi-
enced examiners performed all TE measurements and only
subjects with at least 10 successful measurements and an
interquartile range 30% of the median LSM were
considered for the analysis. Known confounders of reliable
LSM were excluded in all participants. Among others, par-
ticipants without the required fasting period were excluded
(2 Pi*MZ, 2 Pi*ZZ, 3 noncarriers) as well as with serum ALT
or AST activities >5 times the sex-specific ULN or ALP >2
times the sex-specific ULN at the time of recruitment (1
Pi*MZ, 2 Pi*ZZ, 2 noncarriers). CAP was evaluated as a
surrogate for hepatic steatosis.7 We made use of the TE
cutoffs used in the hitherto largest Pi*ZZ cohort,1 which are
in line with etiology-unspecific recommendations.4,7 For
LSM, the cutoff of 7.1 kPa was considered suggestive of
significant liver fibrosis (ie, fibrosis stage 2) and the cutoff
of 10.0 kPa suggestive of advanced liver fibrosis (ie, fibrosis
stage 3). For CAP, the cutoff of 248 dB/m was considered
suggestive of mild steatosis (ie, steatosis grade 1) and the
cutoff of 280 dB/m suggestive of severe steatosis (ie, stea-
tosis grade ¼3).
Ethical Statement. Ethical approval was provided by
the institutional review board of Aachen University (EK
173/15) as well as by the institutional ethics committees at
each study center. All participants issued a written
informed consent form and were treated following the
ethical guidelines of the Helsinki Declaration (Hong Kong
Amendment) as well as Good Clinical Practice (European
guidelines). The study was listed at ClinicalTrials.gov
(NCT029292940).
Analysis in the Population-based UK Biobank
(Cohort 2)
The “UK biobank” (UKB) is a population-based study
comprising 502,617 individuals from the general popula-
tion whose genetic, demographic, and clinical data were
collected between 2006 and 2010 in the United Kingdom. A
total of 487,831 UKB participants were genotyped for both
the Pi*Z and Pi*S mutation; 43,330 participants were
excluded because of Pi*S carriage (either heterozygous/
homozygous or compound heterozygosity with Pi*Z). Our
study has been approved by the UKB Access Committee
(Project #47527).
Histological Analysis of Liver Biopsies (Cohort 3)
Among the total of 84 Pi*MZ and 35 Pi*ZZ individuals,
36 Pi*MZ and all Pi*ZZ subjects were recruited as in-
dividuals with a known AAT deficiency genotype, who had a
medical indication for liver biopsy (ie, elevated LSM 7.1
kPa or repeatedly elevated transaminases). Presence of a
liver comorbidity except NAFLD was excluded as described
for the prospectively recruited participants. The remaining
48 Pi*MZ subjects were gathered from cohorts of biopsied
individuals with cryptogenic (n ¼ 13) or NAFLD-related
liver disease (n ¼ 35). All individuals of these cohorts
were genotyped for the Pi*S and Pi*Z variant and only
Pi*MZ individuals were chosen for histologic analysis. The
analyzed biopsies were from following centers: Aachen (20
Pi*MZ, 32 Pi*ZZ), Hannover (3 Pi*MZ), Munich (2 Pi*MZ),
Salzburg (20 PiMZ, 2 Pi*ZZ), Vienna (13 Pi*MZ), Innsbruck
(3 Pi*MZ), Newcastle (11 Pi*MZ), Madeira (1 Pi*ZZ), and
Sydney (12 Pi*MZ). Only specimens with at least 10 portal
triads were used for analysis (4 Pi*MZ excluded). For each
specimen, the whole sample was analyzed.
Formalin-fixed and paraffin-embedded specimens were
cut onto 5-mm-thick sections and stained with hematoxylin
and eosin, PAS-D, and Sirius red staining. In addition, IHC
labeling with a Pi*Z-specific antibody was carried out.8 All
specimens were assessed by a certified hepatopathologist
(H.D.) in a blinded fashion. The presence of hepatic
inflammation and liver fibrosis was quantified according to
Kleiner’s score.9 Disease activity was further evaluated ac-
cording to the NAFLD Activity Score (NAS).9 The amount of
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AAT inclusion bodies per field was assessed after IHC
staining and was classified as described by Clark et al2: 0,
none; 1, rare (<5 inclusions); 2, few (5–20 inclusions); 3,
many (>20 inclusions).
Biochemical Analysis of Liver Biopsies (Cohort 4)
A total of 20 liver samples were studied (6 Pi*MZ, 7
Pi*ZZ, 7 noncarriers). Only 1 noncarrier had liver metastasis
and this individual was neither part of the prospectively
recruited cohort (no. 1) nor the biopsy cohort (no. 3). Only
nontumor tissue was used for biochemical analysis. Written
informed consent to use excess biopsy material for research
purposes was obtained from all participants.
For total liver lysates, liver specimens were homogenized
in 4 reducing Laemmli buffer (125 mM Tris-HCl [pH 6.8];
4% [wt/vol] sodium dodecyl sulfate [SDS]; 20% [vol/vol]
glycerol; 4% [vol/vol] b-Mercaptoethanol; 0.01% [wt/vol]
bromophenol blue). To obtain soluble and insoluble proteins,
liver tissues were homogenized in nonionic, 1% Triton-X
containing buffer (5 mM EDTA/PBS, pH 7.4, supplemented
with phosphatase and proteinase inhibitors) and centrifuged
at 3174 G for 15 minutes at 4C. Supernatant (soluble pro-
teins) and pellet (insoluble proteins) were then supple-
mented with 4 reducing Laemmli buffer. The isolated
proteins were separated by SDS-polyacrylamide gel electro-
phoresis (SDS-PAGE) followed by transfer to polyvinylidene
difluoride membranes. The membranes were incubated with
AAT (Sigma, A0409, St Louis, MO), keratin-8 (K8, Troma I, St
Louis, MO), or glyceraldehyde-3-phosphate dehydrogenase
(GAPDH; NovusBio, NB300–221, Nordenstadt, Germany)
primary antibodies and species-specific horseradish
peroxidase–coupled secondary antibodies (Invitrogen, Wal-
tham, MA). The resulting signals were visualized by an
enhanced chemiluminescence detection kit (GE Healthcare/
Amersham Biosciences, Little Chalfont, UK) and images were
taken with the luminescent image analyzer ImageQuant
LAS4000 (GE Healthcare, Little Chalfont, UK).
Statistical Analysis
All categorical variables were described as absolute (n)
and relative (%) frequencies and the corresponding con-
tingency tables were analyzed with c2 tests. Continuous
variables were displayed as stated (mainly mean ± standard
deviation) and were analyzed by unpaired, 2-tailed t-tests as
well as by a multivariable linear model to account for
relevant confounders. Distributions among groups were
assessed by univariable and forward-stepwise multiple lo-
gistic regression analyses to calculate ORs. ORs were pre-
sented with their corresponding 95% confidence intervals
given in brackets. Multivariable logistic regression was
performed to test for independent associations (including
age, sex, BMI, diabetes, mean alcohol consumption,
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controlled attenuation parameter [CAP], and AAT serum
level). Unless stated otherwise, the model adjusting for age,
sex, BMI, diabetes, and mean alcohol consumption was used
throughout the manuscript. Nominal P values were given for
all statistical tests. Bonferroni’s correction was used to ac-
count for multiple testing of covariates. Differences were
considered to be statistically significant when P < .05. The
data were analyzed using SPSS Statistics version 23 (IBM
Corp, Armonk, NY) and Prism version 5 (GraphPad,
LaJolla, CA).
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Supplementary Figure 1. Factors associated with liver stiffness measurements indicative of significant and advanced liver
fibrosis in Pi*MZ subjects (Cohort 1). Unadjusted ORs with their corresponding 95% confidence intervals (CI) are shown for
liver stiffness 7.1 kPa indicative of significant liver fibrosis (A) and liver stiffness 10 kPa indicative of advanced liver fibrosis
(B).
Supplementary Figure 2. Liver stiffness and serum GGT in obese and nonobese Pi*MZ individuals compared with corre-
sponding noncarriers (Cohort 1). (A) Scatter plot of liver stiffness measurements determined by transient elastography in obese
and nonobese subgroups, stratified by BMI 30 kg/m2, of Pi*MZ subjects and noncarriers. The dotted lines represent the
following etiology-unspecific cutoff levels1,10: 7.1 kPa (suggestive of fibrosis stage 2), 10.0 kPa (suggestive of fibrosis stage
3), and 13.0 kPa (suggestive of fibrosis stage 4). (B) Scatter plots of serum GGT levels, normalized to the sex-specific ULN,
marked with a dotted line. The shown multivariable P values were adjusted for age, sex, diabetes mellitus, and mean alcohol
consumption.
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Supplementary Figure 3. Comparison of inclusion bodies in Pi*MZ individuals with different clinical and histological features
(Cohort 3). The abundance of inclusion bodies was scored, using IHC, as described2: no, no inclusions visible; rare, inclusions
in up to 5 cells; few, inclusion bodies in 5–20 cells; and many, inclusions in more than 20 cells. Univariate P values are shown in
all panels. (A) Amounts of inclusion bodies in Pi*MZ individuals with age <50 or age 50 years. (B) Amounts of inclusion
bodies per field in female and male Pi*MZ individuals. (C) Amounts of inclusion bodies per field in Pi*MZ individuals with BMI
<30 or 30 kg/m2. (D) Amounts of inclusion bodies per field in Pi*MZ individuals distributed by using Kleiner’s steatosis
scoring system.9 (E) Amounts of inclusion bodies per field in Pi*MZ individuals distributed by the presence of portal inflam-
mation. (F) Amounts of inclusion bodies per field in Pi*MZ individuals distributed by the presence of portal inflammation.
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ALT (% of ULN) 67±38 75±54 76±49 .042 .18 .78 .25
ALT ULN (%) 11 16 18 .068 .25 .65 .20
AST (% of ULN) 63±23 67±37 76±39 .10 .27 .002 .0003
AST ULN (%) 4 6 16 .29 .93 <.0001 <.0001
GGT (% of ULN) 59±52 75±84 114±131 .005 .007 <.0001 .002
GGT ULN (%)a 10 18 33 .002 .030 <.0001 .001
ALP (% of ULN) 60±21 62±20 67±28 .13 .004 .024 .55
ALP ULN (%)b 4 5 9 .51 .012 .015 .13
Bilirubin (% of ULN) 48±36 52±35 60±39 .18 .50 .003 .060
Bilirubin ULN (%) 7 7 11 .81 .96 .044 .34
Platelets (G/L) 255±63 259±67 230±69 .51 .075 <.0001 <.0001
Platelets <150 G/L (%) 2 4 9 .080 .24 .010 .064
INR (units)c 0.97±0.10 1.01±0.17 1.04±0.18 .001 .027 .066 .18
Albumin (g/L) 4.7±0.5 4.6±0.4 4.4±0.5 .081 .003 <.0001 .29
Lipid metabolism
Triglycerides (mg/dL) 126±71 123±90 103±56 .67 .003 .002 .001
Cholesterol (mg/dL) 217±47 208±49 209±42 .031 .24 .82 .19
Quantitative measures are expressed as means and standard deviations or as relative frequencies (%).
INR, international normalized ratio.
aPi*MZ vs noncarriers: adjusted OR ¼ 2.6 [1.1–6.0], Pi*MZ vs Pi*ZZ: adjusted OR ¼ 0.4 [0.2–0.9].
bPi*MZ vs noncarriers: adjusted OR ¼ 5.1 [1.1–23.0], Pi*MZ vs Pi*ZZ: adjusted OR ¼ 0.2 [0.1–0.6].
cOnly patients not taking anticoagulant medication were analyzed. All multivariable analyses were adjusted for age, sex, BMI, presence of diabetes mellitus, and mean































Age (y) 61±7 60±8 60±8 .12 .73
Women (%) 50 59 50 .076 .080
BMI (kg/m2) 26.3±4.8 26.5±4.6 25.0±4.4 .74 .002
Mean alcohol consumption (g/d) 8.0±10.2 4.7±7.7 4.6±7.6 .001 .92
AAT serum level (mg/dL) 140±25 87±18 29±16 <.0001 <.0001
Modifiable risk factors
BMI 30 kg/m2 (%) 21 26 12 .25 .001
Diabetes mellitus (%) 6 7 4 .74 .20
Relevant alcohol intakea (%) 15 9 7 .13 .43
Liver status
ALT (% of ULN) 65±38 75±40 76±49 .016 .82
ALT  ULN (%)b 7 16 16 .008 .96
AST (% of ULN) 62±20 70±28 80±34 .002 .004
AST  ULN (%)c 2 9 20 .007 .007
GGT (% of ULN) 62±52 83±95 122±147 .011 .004
GGT  ULN (%)d 11 20 32 .013 .013
ALP (% of ULN) 62±21 67±24 68±26 .024 .75
ALP  ULN (%) 4 6 12 .46 .066
Bilirubin (% of ULN) 47±28 52±28 61±40 .11 .020
Bilirubin  ULN (%) 8 7 12 .82 .12
Platelets (G/L) 252±61 253±66 228±74 .91 .001
Platelets <150 G/L (%) 3 7 12 .10 .15
INR (units)e 0.97±0.12 1.02±0.24 1.06±0.23 .027 .23
Albumin (g/L) 4.7±0.5 4.5±0.4 4.4±0.5 .014 .025
Liver stiffness (kPa) 4.5±1.3 6.2±8.6 7.3±6.8 .013 .16
Liver stiffness 7.1 kPa (%)f 6 14 32 .015 <.0001
Liver stiffness 10.0 kPa (%)g 1 7 15 .002 .024
CAP (dB/m) 252±55 263±63 263±58 .096 .98
CAP 280 dB/m (%)h 32 42 35 .045 .19
Lipid metabolism
Triglycerides (mg/dL) 129±69 136±89 111±65 .43 .005
Cholesterol (mg/dL) 227±48 2220±50 219±42 .18 .92
Quantitative measures are expressed as mean ± standard deviation or as relative frequency (%). Multivariable were analyses
adjusted for age, BMI, presence of diabetes mellitus, and mean alcohol consumption.
INR, international normalized ratio.
aAlcohol intake > 12 g/d women, > 24 g/d men (Individuals with alcohol consumption > 40 g/d for females or > 60 g/d for
males had been excluded a priori).
bPi*MZ vs noncarriers: Unadjusted OR¼2.5 [1.2–5.2].
cPi*MZ vs noncarriers: Unadjusted OR¼4.2 [1.4–12.9], Pi*MZ vs Pi*ZZ: Unadjusted OR ¼0.4 [0.2–0.8].
dPi*MZ vs noncarriers: Unadjusted OR¼2.1 [1.2–4.0], Pi*MZ vs Pi*ZZ: Unadjusted OR¼0.5 [0.3–0.9].
eOnly patients not taking anticoagulant medication were considered.
fPi*MZ vs noncarriers: Unadjusted OR ¼2.4 [1.2–5.1], Pi*MZ vs Pi*ZZ: Unadjusted OR ¼0.4 [0.2–0.6].
gPi*MZ vs noncarriers: Unadjusted OR ¼13.2 [1.7–101.7], Pi*MZ vs Pi*ZZ: Unadjusted OR¼0.5 [0.2–0.9].
hPi*MZ vs noncarriers: Unadjusted OR ¼1.6 [1.0–2.5].
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Supplementary Table 3.Logistic Regression Models for Liver Stiffness as Noninvasive Surrogate of Liver Fibrosis in Pi*MZ
Subjects vs Noncarriers (Cohort 1)
Liver stiffness 7.1 kPa Liver stiffness 10 kPa
Odds ratio (OR) [95% CI] P value Odds ratio (OR) [95% CI] P value
Unadjusted 4.2 [1.8–9.8] .001 9.0 [1.1–70.7] .037
Adjusted for age and sex 5.3 [2.2–12.7] .0002 10.4 [1.3–84.0] .028
Adjusted for BMI, DM, and mean
alcohol consumption
3.8 [1.6–9.0] .003 8.1 [1.006–65.331] .049
Adjusted for CAP 4.2 [1.8–9.6] .001 8.9 [1.1–70.2] .038
Adjusted for AAT serum level 5.9 [1.8–18.7] .003 38.8 [3.0–503.1] .005
Adjusted for age, sex, and CAP 5.0 [2.1–11.9] .0003 9.6 [1.2–77.3] .033
Adjusted for age, sex, BMI, DM, and mean
alcohol consumption
4.8 [2.0–11.8] .001 9.3 [1.1–77.2] .040
Adjusted for all above 6.2 [1.7–23.2] .007 64.1 [3.3–1256.6] .006
“Unadjusted” represents the comparison between Pi*MZ individuals and noncarriers without accounting for the mentioned
cofactors. The cutoff for liver stiffness measured by transient elastography (TE) was selected based on etiology-unspecific
recommendations, ie, 7.1 kPa suggesting the presence of significant fibrosis (fibrosis stage 2) and 10 kPa suggesting
the presence of advanced fibrosis (fibrosis stage 3).
CI, confidence interval; CAP, controlled attenuation parameter; DM, diabetes mellitus. P values <.05 are indicated in bold font.
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Supplementary Table 4.Characteristics of Pi*ZZ Subjects and Pi*MZ Individuals, Both With LSM Suggesting Significant Liver
Fibrosis (Cohort 1)
Pi*ZZ, LSM 7.1 kPa n¼78 Pi*MZ, LSM 7.1 kPa n¼42 P value (univariable)
Characteristics
Age (years) 55±14 51±15 .12
Women (%) 32 43 .24
BMI (kg/m2) 26.1±5.9 28.3±4.6 .046
Mean alcohol consumption (g/d) 3.8±6.2 3.4±7.0 .78
Modifiable risk factors
BMI 30 kg/m2 (%)a 16 42 .002
Diabetes mellitus (%)b 3 17 .016
Relevant alcohol intakec (%) 6 3 .42
Liver status
ALT (% of ULN) 100±75 90±56 .47
ALT ULN (%) 36 20 .069
AST (% of ULN) 97±62 75±38 .047
AST ULN (%)d 33 13 .025
GGT (% of ULN) 195±201 112±128 .022
GGT ULN (%)e 55 33 .029
ALP (% of ULN) 74±35 71±34 .69
ALP ULN (%) 18 5 .065
Bilirubin (% of ULN) 70±44 59±34 .19
Bilirubin ULN (%) 17 10 .33
Platelet count (G/L) 192±64 239±68 .001
Platelets <150 G/L (%) 25 13 .12
INR (units)f 1.13±0.31 1.04±0.09 .16
Albumin (g/L) 4.3±0.5 4.6±0.4 .012
Liver stiffness (kPa) 13.2±11.6 14.7±16.0 .54
CAP (dB/m) 274±63 272±61 .88
CAP 280 dB/m (%) 48 53 .67
Lipid metabolism
Triglycerides (mg/dL) 114±60 140±90 .075
Cholesterol (mg/dL) 213±50 206±61 .52
Quantitative measures are expressed as means and standard deviations or as relative frequencies (%).
INR, international normalized ratio.
aUnadjusted OR¼0.3 [0.1–0.6].
bUnadjusted OR¼0.2 [0.0–0.8].
cAlcohol intake >12 g/d women, >24 g/d men (Individuals with alcohol consumption >40 g/d for females or >60 g/d for males
had been excluded a priori).
dUnadjusted OR¼0.3 [0.1–0.9].
eUnadjusted OR¼0.4 [0.2–0.9].
fOnly patients not taking anticoagulant medication were considered. P values <.05 are indicated in bold font.
548.e8 Schneider et al Gastroenterology Vol. 159, No. 2
Supplementary Table 5.Characteristics of Pi*MZ Subjects With and Without LSM Suggesting Significant Liver Fibrosis
(Cohort 1)
Pi*MZ, LSM <7.1 kPa n¼377 Pi*MZ, LSM 7.1 kPa n¼42 P value (univariable)
Characteristics
Age (years)a 44±16 51±15 .013
Women (%) 58 43 .069
BMI (kg/m2)b 25.7±4.6 28.3±4.6 .001
Mean alcohol consumption (g/d) 4.5±6.7 3.4±7.0 .36
AAT serum level (mg/dL) 87±20 90±19 .49
Modifiable risk factors
BMI 30 kg/m2 (%)c 16 42 <.0001
Diabetes mellitus (%)d 3 17 <.0001
Relevant alcohol intakee (%) 7 3 .30
Liver status
Liver stiffness (kPa) 4.5±1.1 14.7±16.0 <.0001
CAP (dB/m)f 242±60 272±61 .004
CAP 248 dB/m (%)g 46 72 .003
CAP 280 dB/m (%)h 27 53 .001
ALT (% of ULN) 73±54 90±56 .065
ALT ULN (%) 16 20 .49
AST (% of ULN) 66±36 75±38 .13
AST ULN (%)h 5 13 .044
GGT (% of ULN) 71±78 112±128 .004
GGT ULN (%)i 16 33 .009
ALP (% of ULN) 61±18 71±34 .004
ALP ULN (%) 4 5 . 72
Bilirubin (% of ULN) 51±35 59±34 .14
Bilirubin ULN (%) 6 10 .36
Platelet count (G/L) 261±64 239±88 .059
Platelets <150 G/L (%)j 3 13 .006
INR (units)k 1.01±0.18 1.04±0.09 .30
Albumin (g/L) 4.6±0.4 4.6±0.4 .41
Lipid metabolism
Triglycerides (mg/dL) 121±90 140±89 .21
Cholesterol (mg/dL) 209±48 206±61 .77
Quantitative measures are expressed as means and standard deviations or as relative frequencies (%).





eAlcohol intake >12 g/d women, >24 g/d men (Individuals with alcohol consumption >40 g/d for females or >60 g/d for males






kOnly patients not taking anticoagulant medication were considered. P values <.05 are indicated in bold font.
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Age (years) 44±16 47±14 .11
Women (%) 58 51 .33
BMI (kg/m2) 25.7±4.6 27.0±4.4 .036
Mean alcohol consumption (g/d) 4.1±5.7 5.9±10.3 .053
AAT serum level (mg/dL) 87±19 88±25 .91 .71
Modifiable risk factors
BMI 30 kg/m2 (%) 21 34 .016
Diabetes mellitus (%) 3 7 .12
Relevant alcohol intakea (%) 6 10 .22
Liver status
ALT (% of ULN) 64±28 121±98 <.0001 <.0001
ALT  ULN (%)b 9 47 <.0001 <.0001
AST (% of ULN) 62±21 86±69 <.0001 <.0001
AST  ULN (%)c 3 18 <.0001 <.0001
GGT (% of ULN) 47±20 203±134 <.0001 <.0001
ALP (% of ULN) 59±17 75±29 <.0001 <.0001
ALP  ULN (%)d 3 15 <.0001 <.0001
Bilirubin (% of ULN) 51±35 75±29 .58 .54
Bilirubin  ULN (%) 7 7 .82 .78
Platelets (G/L) 260±68 252±64 .32 .50
Platelets <150 G/L (%) 4 6 .45 .50
INR (units)e 1.01±0.18 0.99±0.12 .44 .36
Albumin (g/L) 4.6±0.4 4.6±0.5 .68 .49
Liver stiffness (kPa)f 4.8±2.2 8.5±13.2 <.0001 <.0001
Liver stiffness 7.1 kPa (%)g 8 18 .009 .060
Liver stiffness 10.0 kPa (%)h 2 13 <.0001 .001
CAP (dB/m)i 240±59 263±61 .005 .11
CAP 248 dB/m (%)j 44 69 .0002 .005
CAP 280 dB/m (%)k 25 47 .0002 .008
Lipid metabolism
Triglycerides (mg/dL)l 114±76 162±130 <.0001 .0004
Cholesterol (mg/dL) 206±48 219±53 .057 .069
Quantitative measures are expressed as mean ± standard deviation or as relative frequency (%). Multivariable analyses were
adjusted for age, BMI, presence of diabetes mellitus, mean alcohol consumption, and controlled attenuation parameter (CAP).
INR, international normalized ratio.
aAlcohol intake >12 g/d women, >24 g/d men (Individuals with alcohol consumption >40 g/d for females or >60 g/d for males











lAdjusted OR¼1.004 [1.001–1.007]. P values <.05 are indicated in bold font.
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Supplementary Table 7.Logistic Regression Models for Elevated Serum GGT in Pi*MZ Subjects vs Noncarriers (Cohort 1)
GGT ULN
Odds ratio
(OR) [95% CI] P value
Unadjusted 2.3 [1.3–4.0] .004
Adjusted for age and sex 2.6 [1.4–4.5] .001
Adjusted for BMI, DM, and mean alcohol consumption 2.4 [1.3–4.2] .003
Adjusted for CAP 2.3 [1.3–4.0] .004
Adjusted for AAT serum level 2.5 [1.1–5.7] .025
Adjusted for age, sex, and CAP 2.5 [1.4–4.4] .002
Adjusted for age, sex, BMI, DM, and mean
alcohol consumption
2.6 [1.4–4.7] .002
Adjusted for all above 2.9 [1.2–6.8] .018
“Unadjusted” represents the comparison between Pi*MZ individuals and noncarriers without accounting for the mentioned
cofactors. The sex-specific ULN was used.
CI, confidence interval; CAP, controlled attenuation parameter; DM, diabetes mellitus. P values <.05 are indicated in bold font.
Supplementary Table 8.Characteristics of Pi*MZ Individuals in the Europe-wide Registry (Cohort 1) and Those Who Received
Liver Biopsy (Cohort 2)
Pi*MZ, registry (cohort 1)
n¼419





Age (years) 45±16 55±16 <.0001
Women (%) 56 44 <.0001
BMI (kg/m2) 26.0±4.6 31.4 ± 6.5 <.0001
Mean alcohol consumption (g/d) 4.4±.6.8 5.1 ± 10.3 .45
Modifiable risk factors
BMI 30 kg/m2 (%) 18 61 <.0001
Diabetes mellitus (%) 4 31 <.0001
Relevant alcohol intakea (%) 7 5 .14
Quantitative measures are expressed as mean ± standard deviation (except liver stiffness: median and interquartile range) or
as relative frequency (%).
aAlcohol intake >12 g/d women, >24 g/d men (individuals with alcohol consumption >40 g/d for females or >60 g/d for males
had been excluded a priori). P values <.05 are indicated in bold font.
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